Samuel D Riccitelli
CIK 1414839 · Interim President and CEO · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$567.7K
Companies
5
Total Filings
49
Lifetime Open-Market Net
-$3.99M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KIDS | Director | 31,859 | $17.82 | $567.7K | $0 | 9 | 2026-06-10 |
| BIOCEPT INC (BIOC) Delisted | Interim President and CEO | — | $0.43 | — | $0 | 3 | 2022-03-02 |
| PRPO | Director | — | $22.10 | — | $0 | 3 | 2019-03-20 |
| Viridian Therapeutics, Inc.\DE (SGNL) Delisted | President & CEO | 571,370 | — | — | $11.1K | 7 | 2016-11-02 |
| GENOPTIX INC (GXDX) Delisted | Ex VP and COO | 49 | — | — | -$4.01M | 27 | 2011-03-07 |
Recent Filings · Page 2 of 5
49 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-07 | KIDS | Grant (A) | +1,400 | $0 | EDGAR |
| 2019-03-20 | PRPO | Grant (A) | — | $0 | EDGAR |
| 2018-06-22 | KIDS | Grant (A) | +1,400 | $0 | EDGAR |
| 2018-02-21 | PRPO | Grant (A) | — | $0 | EDGAR |
| 2017-09-28 | PRPO | Grant (A) | — | $0 | EDGAR |
| 2016-11-02 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Mixed | +96,840 | -$37.1K | EDGAR |
| 2016-06-30 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Mixed | +59,416 | -$29.8K | EDGAR |
| 2016-05-19 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-02-12 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Mixed | +69,984 | -$25.0K | EDGAR |
| 2015-11-23 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Buy (P) | +14,000 | $11.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.